Report of Foreign Issuer (6-k)
May 08 2018 - 4:16PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May, 2018
Commission File Number: 001-35892
GW PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Other Events
On May 8, 2018, GW Pharmaceuticals plc
(the “Company”) issued a press release announcing its second quarter 2018 financial results and operational progress
and details of a conference call to be held at 4:30 p.m. EST on May 8, 2018 to discuss the results and operational progress. The
Company’s unaudited condensed consolidated interim financial statements as of March 31, 2018 are attached as Exhibit 99.1
and incorporated by reference herein. The Company’s Management’s Discussion and Analysis of Financial Condition and
Results of Operations is attached as Exhibit 99.2 and incorporated by reference herein. Exhibits 99.1 and 99.2 to this Report on
Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-217329)
and Form S-8 (Registration Numbers 333-204389 and 333-217328), and related Prospectuses, as such Registration Statements
and Prospectuses may be amended from time to time and to be a part thereof from the date on which this report is filed, to the
extent not superseded by documents or reports subsequently filed or furnished.
The press release is attached as Exhibit
99.3 and is incorporated by reference herein. Exhibit 99.3 to this Report on Form 6-K shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”) or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933 or the Exchange Act.
EXHIBIT INDEX
|
Exhibit
|
Description of Exhibit
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
GW Pharmaceuticals plc
|
|
|
|
|
|
|
By:
|
/s/ Douglas B. Snyder
|
|
|
Name:
|
Douglas B. Snyder
|
|
|
Title:
|
Chief Legal Officer
|
|
|
|
|
|
Date: May 8, 2018
|
|
|